OP0072 LOW-DOSE COLCHICINE IS ASSOCIATED WITH LOWER INCIDENCE OF KNEE AND HIP REPLACEMENTS: A POST-HOC ANALYSIS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Background Osteoarthritis is a major contributor to pain and disability worldwide [1]. Considering that inflammation plays an important role in the development of osteoarthritis, anti-inflammatory drugs may slow progression disease [2]. Objectives To examine whether years-long use colchicine 0.5 mg daily reduces incident total knee replacements (TKRs) hip (THRs). Methods We performed post-hoc analysis data collected LoDoCo2 trial determine time first or replacement. A Cox proportional hazard model was used estimate ratios (HRs) 95% confidence intervals (CIs) for once as compared placebo. Sensitivity analyses were by excluding patients known with gout at baseline (to avoid possible carry-over effects prevent attacks) who had joint surgery within 3 months after randomization any bias related planned prior randomization). All on intention-to-treat basis. Results Among 5522 randomized participants, 2762 received 2760 placebo during median duration follow-up 28.6 (interquartile range, 20.5 44.4). The mean (SD) age 66 (8.6) years 846 (15.3%) female. During trial, TKR/ THR 68 (2.5%) group 97 (3.5%) (HR, 0.69; CI, 0.51-0.95; p = 0.02) (Table 1 Figure 1). In sensitivity excluded similar results obtained, while omitting took place three yielded even larger rate reduction Table 1. Incidence rates according treatment. Trial cohort/subgroup Placebo (n=2760) Colchicine (n=2762) Hazard ratio (95% CI) No. patients/total no. (% ) events/100 person-yrs Full population events 97/2760 (3.5) 1.30 68/2762 (2.5) 0.90 0.69 (0.51-0.95) Participants 89/2534 61/2542 (2.4) 0.88 0.68 (0.49-0.94) 96/2760 1.29 59/2762 (2.1) 0.78 0.61 (0.44-0.84) THR= replacement/ replacement Cumulative incidence knee/hip full population. participants receiving comparison daily. Data are shown enlarged y-axis. Conclusion this associated reduced risk THR. Further investigation long-term therapy osteoarthritis warranted. References [1]Cross M, Smith E, Hoy D, et al. global burden osteoarthritis: Estimates from Global Burden Disease 2010 study. Ann Rheum Dis. 2014;73(7):1323–30. [2]Schieker Conaghan PG, Mindeholm L, Effects interleukin-1β inhibition replacement: Exploratory randomized, double-blind, placebo-controlled trial. Intern Med. 2020;173(7):509–15. Acknowledgements: NIL. Disclosure Interests None Declared.